News and Trends 1 Dec 2015
How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies
Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be granted clinical and regulatory validation so far… After the acquisition in 2012 of Micromet, the Munich-based company that first developed Blinatumomab, Amgen kept revealing the potential of this powerful protein… Blincyto was then approved by the FDA as an orphan […]